GlaxoSmithKline health news articles

Tykerb with Herceptin increases advanced breast cancer survival
An investigational combination of TYKERB (lapatinib) plus HERCEPTIN (trastuzumab) proved a median survival of 14 months in women with an aggressive form of breast cancer.

GSK to fight HIV AIDS in Africa
GlaxoSmithKline's CEO Andrew Witty announced a series of new initiatives targeted at improving research, development, and access to HIV/AIDS medicines for children in Sub-Saharan Africa and supporting healthcare for people living with HIV and AIDS.

GSK's cervical cancer vaccine Cervarix got WHO prequalification
The World Health Organization (WHO) has awarded prequalification to Cervarix, GlaxoSmithKline's cervical cancer vaccine. GlaxoSmithKline pharmaceutical company applied for WHO prequalification of Cervarix 2 years ago.

Avandia has no increased overall heart risk
Clinical trial results presented at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.

GSK to manufacture A H1N1 influenza vaccine
GSK is committed to supporting governments and health authorities around the world to respond to the emergence of the new A (H1N1) influenza strain.

GSK launches OTC weight loss drug alli, orlistat in Europe
GlaxoSmithKline (GSK) has announced that alli – the first clinically proven over the counter weight loss aid – is available in pharmacies across Europe.

GSK and Pfizer to create a new HIV company
GlaxoSmithKline plc (GSK) and Pfizer Inc (PFE) announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialisation of HIV medicines.

GSK's alli for weight loss approved in Europe
A decision made by the European Commission opens access to a treatment that could help people who are overweight and obese.

GSK statement on MHRA Seroxat investigation
GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine).

GSK reduces HIV drugs prices for poor countries
GSK today announced significant new price reductions for its HIV medicines offered on a not-for-profit basis to the world's poorest countries. This reduction is the fifth time the company has made a price reduction as part of its pioneering preferential pricing policy originally introduced in 1997.

Health news organizations - G

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
4.18